Clinical Trial Update: Micafungin Versus AmBisome in Invasive Candidiasis and Candidemia [Phase 3]

View source ↗

Summary

Phase 3 trial comparing micafungin to liposomal amphotericin B (AmBisome) for invasive candidiasis and candidemia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Candidemia
• Invasive Candidiasis

Drugs mentioned

• AMBISOME (AMPHOTERICIN B)
• Micafungin (micafungin)

Snippet

Sponsor: Astellas Pharma Inc | Conditions: Candidiasis | Phase 3 | Status: COMPLETED